Evkeeza Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Evkeeza market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the implementation of supportive regulations and policies, rapid advancements in genomics and personalized medicine, an aging population, favorable government initiatives, and the emergence of conditions such as birth defects.

Growth during the market's forecast will be driven by the increasing prevalence of hypercholesterolemia, the rising incidence of rare diseases globally, the growing impact of rare neurological disorders, and higher healthcare spending. Key trends during the forecast period include the development of specialized treatments, personalized medicine, the rise of telemedicine and remote monitoring, the expansion of patient support programs, and new regulatory approvals.

The increasing prevalence of genetic disorders is expected to drive the growth of the evkeeza market in the future. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, resulting from mutations in one or more genes or changes in the structure or number of chromosomes. The rise in genetic disorders is linked to advancements in diagnostic technologies and the growing environmental factors contributing to these conditions. Evkeeza is used to treat homozygous familial hypercholesterolemia (HoFH), a genetic disorder, by inhibiting ANGPTL3 to lower LDL cholesterol levels in affected patients. For example, in June 2024, the American Society of Hematology reported that by 2050, the global population of individuals with sickle cell disease (SCD) is expected to increase by about 30%. As a result, the rising prevalence of genetic disorders is fueling the growth of the evkeeza market.

The growing number of drug approvals is also expected to boost the expansion of the evkeeza market in the coming years. Drug approvals refer to the formal evaluation and authorization process by regulatory authorities for the use of pharmaceutical drugs in public health. The increase in drug approvals is driven by advances in biotechnology, which enable quicker drug discovery, and supportive regulatory frameworks, such as accelerated approval programs, that streamline the process for medications in high demand. These drug approvals help expand Evkeeza’s availability for treating homozygous familial hypercholesterolemia, improve patient access, and take advantage of incentives such as orphan drug exclusivity. For instance, in January 2024, ALM GlobalProperties, LLC reported that the U.S. Food and Drug Administration approved nearly 50% more new drugs in the past year compared to 2022. Thus, the rising number of drug approvals is contributing to the growth of the evkeeza market.

A key trend in the evkeeza market is obtaining regulatory approvals for drugs to broaden its reach and strengthen its role in treating patients with homozygous familial hypercholesterolemia (HoFH). Regulatory approvals refer to the official authorization from governmental or regulatory agencies for a drug, medical device, or treatment to be marketed and used by the public. For example, in March 2023, Regeneron Pharmaceuticals Inc. received FDA approval for Evkeeza (evinacumab-dgnb) for children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes extremely high LDL cholesterol levels. This approval marked the first ANGPTL3 inhibitor authorized for this age group, offering a new treatment option for approximately 1,300 affected children in the U.S. Clinical trials showed that children treated with Evkeeza, along with other lipid-lowering therapies, experienced an average 48% reduction in LDL-C levels after 24 weeks.

The key company operating in the evkeeza market is Regeneron Pharmaceuticals Inc.

North America was the largest region in the evkeeza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in evkeeza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the evkeeza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Evkeeza (evinacumab) is a monoclonal antibody used to treat homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by high cholesterol levels. It works by inhibiting angiopoietin-like 3 (ANGPTL3), which helps reduce LDL cholesterol and other lipid levels in patients affected by the condition.

The primary indications for evkeeza are primary hypercholesterolemia and homozygous familial hypercholesterolemia. Primary hypercholesterolemia is a condition marked by elevated cholesterol levels in the blood, typically caused by genetic or hereditary factors, rather than lifestyle or other medical conditions. Evkeeza is administered via intravenous (IV) infusion, self-administration, subcutaneous (SC) injection, hospital infusion centers, and ambulatory care settings. It is distributed through hospital pharmacies, specialty pharmacies, and online pharmacies.

The evkeeza market research report is one of a series of new reports that provides evkeeza market statistics, including evkeeza industry global market size, regional shares, competitors with an evkeeza market share, detailed evkeeza market segments, market trends and opportunities, and any further data you may need to thrive in the evkeeza industry. This evkeeza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The evkeeza market consists of sales of products including Repatha (evolocumab), Praluent (alirocumab), and Lomitapide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.